UnitedHealthcare publishes updated GLP-1 quantity limits for September 1, 2026

UnitedHealthcare has published an updated "Quantity Duration Limits" document, dated August 21, 2026, that takes effect September 1, 2026, and sets specific monthly caps for the GLP-1 drugs it covers on commercial plans ^[1]. The list applies to Ozempic, Wegovy, Mounjaro, Zepbound and Saxenda, and spells out how many pens, tablets or vials a member can fill in a given period ^[1].

For Wegovy, the cap is four pens per month, with 30 tablets per month for the oral form, but the 1.5 mg, 4 mg and 9 mg tablet strengths are limited to 60 tablets over 365 days rather than a flat monthly number ^[1]. Zepbound is capped at four autoinjectors or vials per month, but only one KwikPen per month, a notably tighter limit for that specific pen device ^[1]. Ozempic is limited to one pen per month, Mounjaro to four pens per month, and Saxenda to five pens per month ^[1].

The document also adds a fill-sequencing rule across these drugs: members must receive two separate one-month fills before they become eligible for a three-month supply ^[1]. That means someone starting on one of these medications cannot immediately move to a 90-day fill, even if their plan otherwise allows extended supplies.

The published list is part of a much larger, alphabetized document covering hundreds of drugs beyond GLP-1 medications, and it carries a standard disclaimer that being named on the list does not by itself mean a drug is covered under any particular plan ^[1]. The source does not say whether these specific numbers represent a change from a prior version of the list, since only the "last updated" date is given, not a comparison to earlier limits ^[1].

Why it matters for patients

Quantity limits like these do not decide whether a drug is covered at all — that depends on a member's specific plan design and formulary — but they do control how much can be dispensed at one time once a prescription is approved ^[1]. For someone titrating up through Wegovy's dose strengths, the 60-tablets-per-365-days rule on the 1.5 mg, 4 mg and 9 mg oral doses could matter if a prescriber wants to move through doses faster than that pace allows, since the source does not spell out how exceptions or overrides would work for that particular limit ^[1].

The gap between Zepbound's autoinjector/vial limit (four per month) and its KwikPen limit (just one per month) is also worth noting, since it treats what is broadly the same drug differently depending on which device format is prescribed ^[1]. Patients and prescribers who are not aware of these device-specific caps could be surprised at the pharmacy counter.

The new two-fill-before-90-days rule affects anyone hoping to move quickly to a three-month supply, which is sometimes used to lower per-fill costs or reduce trips to the pharmacy. Under this rule, that option is not available until after two standard monthly fills have already gone through ^[1].

What happens next

The limits are dated to take effect September 1, 2026, according to the document itself ^[1]. The source does not specify whether the plan intends further updates before or after that date, nor does it indicate how member appeals or medical exceptions to these specific quantity limits would be handled ^[1]. Patients with UnitedHealthcare commercial coverage who use these medications may want to check with their plan or pharmacy directly about how the September 1 limits apply to their specific benefit design, since the published list itself does not guarantee coverage under any individual plan ^[1].